Odevixibat

Generic Name
Odevixibat
Brand Names
Bylvay, 蓓尔唯
Drug Type
Small Molecule
Chemical Formula
C37H48N4O8S2
CAS Number
501692-44-0
Unique Ingredient Identifier
2W150K0UUC
Background

Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familiar intrahepatic cholestasis (PFIC). Odevixibat is the first approved non-surgical treatment option for PFIC. Previous therapies for PFIC included a bile acid sequestrant such as ursodeoxycholic acid.

Odevixibat was granted FDA approval on 20 July 2021.

Indication

Odevixibat is indicated for the treatment of pruritus in patients older than 3 months with progressive familiar intrahepatic cholestasis (PFIC) and cholestatic pruritus in patients 12 months of age and older with Alagille Syndrome. It may not be effective in patients with PFIC type 2 with ABCB11 variants since these patients lack a functional bile salt export pump.

Associated Conditions
Cholestatic pruritus, Pruritus
Associated Therapies
-
© Copyright 2024. All Rights Reserved by MedPath